Effect of Sex on Clinical Outcomes in Patients with Coronavirus Disease: A Population-Based Study.
clinical outcome
coronavirus disease
mortality
sex
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
24 Dec 2020
24 Dec 2020
Historique:
received:
27
10
2020
revised:
15
12
2020
accepted:
22
12
2020
entrez:
30
12
2020
pubmed:
31
12
2020
medline:
31
12
2020
Statut:
epublish
Résumé
This study aimed to evaluate the association between sex and clinical outcomes in patients with coronavirus disease (COVID-19) using a population-based dataset. In this retrospective study, insurance claims data from the Korea database were used. Patients who tested positive for COVID-19 were included in the study. All diseases were defined according to the International Classification of Diseases 10th revision. During follow-up, the clinical outcomes, except mortality, were assessed using the electrical codes from the dataset. The clinical outcomes noted were: hospitalization, the use of inotropics, high flow nasal cannula, conventional oxygen therapy, mechanical ventilation, extracorporeal membrane oxygenation, development of acute kidney injury, cardiac arrest, myocardial infarction, acute heart failure, pulmonary embolism, and disseminated intravascular coagulation after the diagnosis of COVID-19. A total of 7327 patients were included; of these, 2964 patients (40.5%) were men and 4363 patients (59.5%) were women. There were no significant differences in the Charlson comorbidity index score between men and women in the same age group. The incidence of mortality and clinical outcomes was higher among men than among women. The mortality rate was the highest for the populations aged 50-64 or ≥65 years. The subgroup analyses for age, diabetes mellitus, or hypertension showed favorable results for patient survival or clinical outcomes for women compared to men. Our population-based study showed that female patients with COVID-19 were associated with favorable outcomes. Furthermore, the impact of sex was more evident in patients aged 50-64 or ≥65 years.
Sections du résumé
BACKGROUND
BACKGROUND
This study aimed to evaluate the association between sex and clinical outcomes in patients with coronavirus disease (COVID-19) using a population-based dataset.
METHODS
METHODS
In this retrospective study, insurance claims data from the Korea database were used. Patients who tested positive for COVID-19 were included in the study. All diseases were defined according to the International Classification of Diseases 10th revision. During follow-up, the clinical outcomes, except mortality, were assessed using the electrical codes from the dataset. The clinical outcomes noted were: hospitalization, the use of inotropics, high flow nasal cannula, conventional oxygen therapy, mechanical ventilation, extracorporeal membrane oxygenation, development of acute kidney injury, cardiac arrest, myocardial infarction, acute heart failure, pulmonary embolism, and disseminated intravascular coagulation after the diagnosis of COVID-19.
RESULTS
RESULTS
A total of 7327 patients were included; of these, 2964 patients (40.5%) were men and 4363 patients (59.5%) were women. There were no significant differences in the Charlson comorbidity index score between men and women in the same age group. The incidence of mortality and clinical outcomes was higher among men than among women. The mortality rate was the highest for the populations aged 50-64 or ≥65 years. The subgroup analyses for age, diabetes mellitus, or hypertension showed favorable results for patient survival or clinical outcomes for women compared to men.
CONCLUSION
CONCLUSIONS
Our population-based study showed that female patients with COVID-19 were associated with favorable outcomes. Furthermore, the impact of sex was more evident in patients aged 50-64 or ≥65 years.
Identifiants
pubmed: 33374452
pii: jcm10010038
doi: 10.3390/jcm10010038
pmc: PMC7794723
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Yeungnam University Medical Center
ID : The 2020 Yeungnam University Medical Center COVID-19 Research Grant
Références
Exp Biol Med (Maywood). 2017 Aug;242(14):1412-1423
pubmed: 28661206
Sci Immunol. 2018 Jan 26;3(19):
pubmed: 29374079
Ann Intern Med. 2020 Sep 1;173(5):385-386
pubmed: 32384135
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Prehosp Disaster Med. 2020 Aug;35(4):438-441
pubmed: 32600476
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
J Immunol. 2006 Aug 15;177(4):2088-96
pubmed: 16887967
Biol Sex Differ. 2010 Nov 05;1(1):6
pubmed: 21208466
PLoS One. 2020 Nov 17;15(11):e0241955
pubmed: 33201896
BMC Public Health. 2020 Nov 19;20(1):1742
pubmed: 33213391
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
N Engl J Med. 2020 Apr 23;382(17):1653-1659
pubmed: 32227760
Clin Infect Dis. 2020 Jul 28;71(15):863-865
pubmed: 32232322
Diabetes Metab J. 2020 Oct;44(5):671-678
pubmed: 33115211
Am J Obstet Gynecol. 2020 Sep;223(3):453-454
pubmed: 32460973
Curr Opin Pharmacol. 2006 Jun;6(3):271-6
pubmed: 16581295
Am J Infect Control. 2020 Sep;48(9):1080-1086
pubmed: 32522606
BMJ Open. 2017 Jul 10;7(7):e013736
pubmed: 28698314
Cancer Discov. 2020 Jun;10(6):779-782
pubmed: 32276929
Am J Physiol Lung Cell Mol Physiol. 2020 Jun 1;318(6):L1280-L1281
pubmed: 32432918
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Nat Rev Immunol. 2020 Jul;20(7):442-447
pubmed: 32528136
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nat Rev Endocrinol. 2013 Jan;9(1):56-62
pubmed: 23183675